Acquisition of Common Shares of Cannara Biotech Inc.

Rhea-AI Summary

Cannara Biotech Inc. (TSXV: LOVE, OTCQB: LOVFF) announced that on August 31, 2022, Derek Stern, a director and principal shareholder, acquired 720,000 common shares at $0.112 each, amounting to $80,285 CAD. After the purchase, Stern's ownership increased to 164,370,184 shares, representing 18.74% of the total shares on a partially diluted basis. The acquisition, made for investment purposes, indicates Stern's confidence in Cannara's future, as he may also acquire additional securities in the future. This press release complies with National Instrument 62-103, detailing insider reporting obligations.

Positive

• Derek Stern acquired additional shares, indicating confidence in the company's growth.
• Mr. Stern's ownership increased to 18.74%, a sign of commitment to Cannara's future.

Negative

• None.

MONTREAL, Sept. 1, 2022 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec, announced that on August 31, 2022, Derek Stern, a director and principle shareholder owning more than 10% of the issued and outstanding common shares ("Common Shares") of Cannara, acquired 720,000 common shares ("Purchased Shares") in the capital of Cannara, representing approximately 0.08% of the Common Shares in the capital of the Company (the "Acquisition").

The Purchased Shares were acquired through normal course purchases through the facilities of the TSX Venture Exchange for $0.112 Canadian dollars per Purchased Shares, for an aggregate amount equal to $80,285 Canadian dollars.

Prior to the Acquisition, Mr. Stern, through controlling interests in Olymbec Investments Inc., directly and indirectly, owned 163,650,184 Common Shares and 100,000 options to purchase Common Shares ("Options"), representing approximately 18.66% of issued and outstanding Common Shares on a partially diluted basis. After the Acquisition, Mr. Stern, through controlling interests in Olymbec Investments Inc., directly and indirectly, owns 164,370,184 Common Shares and 100,000 Options, representing approximately 18.74% of the issued and outstanding Common Shares on a partially diluted basis.

Mr. Stern acquired the Purchased Shares for investment purposes. Mr. Stern may from time to time acquire additional securities of the Company, dispose of some or all of the existing or additional securities or may continue to hold the securities.

This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. A copy of the related early warning report is being filed with the applicable securities commissions and will be made available under the Company's profile on SEDAR (www.sedar.com). Cannara's head office is located at 333 Decarie Blvd, Suite 200, Montreal, Quebec, H4N 3M9. Mr. Stern's principal office address is 333 Decarie Blvd, Suite 500, Montreal, Quebec, H4N 3M9.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Québec and Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 125,000kg of potential annualized cultivation output. Leveraging Québec's low electricity costs, Cannara's facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/acquisition-of-common-shares-of-cannara-biotech-inc-301616447.html

SOURCE Cannara Biotech Inc.

FAQ

What recent acquisition did Derek Stern make in Cannara Biotech?

On August 31, 2022, Derek Stern acquired 720,000 common shares at $0.112 each.

How much did Derek Stern spend on his recent share acquisition in Cannara?

Derek Stern spent $80,285 CAD on the acquisition of 720,000 shares.

What percentage of Cannara’s shares does Derek Stern own after the acquisition?

After the acquisition, Derek Stern owns approximately 18.74% of Cannara's issued shares.

Is Derek Stern considering acquiring more shares in Cannara Biotech?

Yes, Derek Stern may acquire additional securities in Cannara Biotech in the future.

What is the purpose of Derek Stern's acquisition of Cannara shares?

Derek Stern acquired the shares primarily for investment purposes.